Immunosuppressive factors secreted by human amniotic epithelial cells

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 3, 2005, Pages 900-907

  Li, Haochuan ^a   Niederkorn, Jerry Y ^a   Neelam, Sudba ^a   Mayhew, Elizabeth ^a   Word, R Ann ^a   McCulley, James P ^a   Alizadeh, Hassan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIBODY; FAS LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 2; MACROPHAGE MIGRATION INHIBITION FACTOR; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; CASPASE 3; IMMUNOSUPPRESSIVE AGENT;

AMNION; AMNION CELL; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CORNEA; CORNEA EPITHELIUM; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INCUBATION TIME; INNATE IMMUNITY; LIVER CELL; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMOTAXIS; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; NEUTROPHIL; PATHOLOGY; PERITONEUM MACROPHAGE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMNION; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CASPASE 3; CASPASES; CELLS, CULTURED; CHEMOTAXIS; EPITHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTROPHILS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 16244371043     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0495     Document Type: Article

References (46)

1. van Herendael BJ, Oberti C, Brosens I. Microanatomy of the human amniotic membranes: a light microscopic, transmission, and scanning electron microscopic study. Am J Obstet Gynecol. 1978;131: 872-880.
2. Dua HS, Azuara-Blanco A. Amniotic membrane transplantation. Br J Ophthalmol. 1999;83:748-752.
3. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995;14:473-484.
4. Kim JC, Tseng SC. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. Korean J Ophthalmol. 1995;9:32-46.
5. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. Ophthalmology. 2000; 107:980-989; discussion 90.
6. Kruse FE, Rohrschneider K, Volcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology. 1999;106:1504-1510; discussion 11.
7. Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. 2000; 84:826-833.
8. Kim JS, Kim JC, Hahn TW, Park WC. Amniotic membrane transplantation in infectious corneal ulcer. Cornea. 2001;20:720-726.
9. Solomon A, Pires RT, Tseng SC. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 2001;108:449-460.
10. Hanada K, Shimazaki J, Shimmura S, Tsubota K. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera. Am J Ophthalmol. 2001;131:324-331.
11. Azuara-Blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. Br J Ophthalmol. 1999; 83:399-402.
12. Shimazaki J, Yang HY, Tsubota K. Amniotic membrane transplantation for ocular surface reconstruction in patients with chemical and thermal burns. Ophthalmology. 1997;104:2068-2076.
13. Choi YS, Kim JY, Wee WR, Lee JH. Effect of the application of human amniotic membrane on rabbit corneal wound healing after excimer laser photorefractive keratectomy. Cornea. 1998;17:389-395.
14. Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res. 2000;70:329-337.
15. He YG, Alizadeh H, Kinoshita K, McCulley JP. Experimental transplantation of cultured human limbal and amniotic epithelial cells onto the corneal surface. Cornea. 1999;18:570-579.
16. Akle CA, Adinolfi M, Welsh KI, Leibowitz S, McColl I. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet. 1981;2:1003-1005.
17. Adinolfi M, Akle CA, McColl I, et al. Expression of HLA antigens, beta 2-microglobulin and enzymes by human amniotic epithelial cells. Nature. 1982;295:325-327.
18. Endo K, Nakamura T, Kawasaki S, Kinoshita S. Human amniotic membrane, like corneal epithelial basement membrane, manifests the alpha5 chain of type IV collagen. Invest Ophthalmol Vis Sci. 2004;45:1771-1774.
19. Shao C, Sima J, Zhang SX, et al. Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci. 2004;45:1758-1762.
20. Robson MC, Krizek TJ. The effect of human amniotic membranes on the bacteria population of infected rat burns. Ann Surg. 1973; 177:144-149.
21. OkitaJR, Sagawa N, Casey ML, Snyder JM. A comparison of human amnion tissue and amnion cells in primary culture by morphological and biochemical criteria. In Vitro. 1983;19:117-126.
22. van Klink F, Taylor WM, Alizadeh H, Jager MJ, van Rooijen N, Niederkorn JY. The role of macrophages in Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1996;37:1271-1281.
23. Hurt M, Proy V, Niederkorn JY, Alizadeh H. The interaction of Acanthamoeba castellanii cysts with macrophages and neutrophils. J Parasitol. 2003;89:565-572.
24. Ren DH, Mayhew E, Hay C, Li H, Alizadeh H, Niederkorn JY. Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci. 2004;45:1162-1168.
25. Alizadeh H, Howard K, Mellon J, Mayhew E, Rusciano D, Niederkorn JY. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest Ophthalmol Vis Sci. 2003;44: 3042-3051.
26. Matsuda A, Tagawa Y, Matsuda H, Nishihira J. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human cornea. FEBS Lett. 1996;385:225-228.
27. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160:5693-5696.
28. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol. 1999;65:137-150.
29. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153:80-82.
30. Lai WC, Bennett M, Johnston SA, Barry MA, Pakes SP. Protection against Mycoplasma pulmonis infection by genetic vaccination. DNA Cell Biol. 1995;14:643-651.
31. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea. 2001;20:408-413.
32. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
33. Tartaglia LA, Rothe M, Hu YF, Goeddel DV. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell. 1993;73:213-2l6.
34. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem. 1998;273:2926-2930.
35. Tseng SC, Prabhasawat P, Lee SH. Amniotic membrane transplantation for conjunctival surface reconstruction. Am J Ophthalmol. 1997;124:765-774.
36. Tseng SC, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. Arch Ophthalmol. 1998;116:431-441.
37. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179:325-335.
38. Solomon A, Rosenblatt M, Monroy D, Ji Z, Pflugfelder SC, Tseng SC. Suppression of interleukin 1alpha and interleukin 1beta in human limbal epithelial cells cultured on the amniotic membrane stromal matrix. Br J Ophthalmol. 2001;85:444-449.
39. Ueta M, Kweon MN, Sano Y, et al. Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction. Clin Exp Immunol. 2002;129:464-470.
40. Mor G, Gutierrez LS, Eliza M, Kahyaoglu F, Ariel A. Fas-fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol. 1998;40:89-94.
41. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
42. Xu JP, Li X, Mori E, et al. Expression of Fas-Fas ligand in murine testis. Am J Reprod Immunol. 1999;42:381-388.
43. Frankel B, Longo SL, Canute GW. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion. J Neurooncol. 2000;48:21-26.
44. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer. 2001;85:1047-1054.
45. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998;282:1714-1717.
46. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today. 1990;11: 237-244.